Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide

Table 4

Fasting and postprandial profiles of the measured parameters in patients receiving exenatide and liraglutide on visit 2.

Parameters	0	120	240	𝑃	𝑃^∗
Triglycerides (mmol/L)
Exenatide	2.16±2.42	2.42±2.37	2.50±2.13	0.040	0.523
Liraglutide	1.72±1.00	1.92±0.94	1.89±0.88	0.030
Total cholesterol (mmol/L)
Exenatide	4.73±1.22	4.72±1.22	4.38±1.87	0.594	0.464
Liraglutide	4.69±1.13	4.70±0.01	4.82±1.03	0.161
HDL (mmol/L)
Exenatide	1.00±0.28	1.01±0.28	1.05±0.28	0.017	0.493
Liraglutide	1.19±0.41	1.17±0.42	1.20±0.43	0.572
LDL (mmol/L)
Exenatide	2.91±1.13	2.92±1.17	3.10±1.29	0.002	0.105
Liraglutide	2.75±0.97	2.71±0.92	2.81±0.90	0.150
Glucose (mmol/L)
Exenatide	6.42±1.46	6.80±2.36	6.07±1.88	0.069	0.710
Liraglutide	6.02±1.15	6.15±1.50	5.30±0.61	0.066
Insulin (pmol/L)
Exenatide	150.75±87.46	233.15±182.40	172.93±175.63	0.143	0.081
Liraglutide	144.53±72.94	413.56±350.00	127.91±84.20	0.026

Data are means ± SD. 𝑃 indicates the result of ANOVA for repeated measurements within each group (𝑃 value for the effect of time); 𝑃^∗ indicates the result of ANOVA for repeated measurements between the two groups (exenatide versus liraglutide) (time × group interaction).